In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $16.90, close to its 52-week low of $13.25.
According to TipRanks.com, Bayko is a 4-star analyst with an average return of 8.6% and a 44.0% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.
Editas Medicine has an analyst consensus of Hold, with a price target consensus of $28.00, representing a 75.7% upside. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $19.00 price target.
Editas Medicine’s market cap is currently $1.16B and has a P/E ratio of -5.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More on EDIT:
- Vivint Smart Home (VVNT) Gets a Hold Rating from Evercore ISI
- Mizuho Securities Remains a Buy on Southwestern Energy (SWN)
- Block (SQ) Receives a Hold from Robert W. Baird
- Analyst Outlook for This Canada’s Energy Sector Company
- Mizuho Securities Maintains Their Buy Rating on Occidental Petroleum (OXY)